|Day's range||5.00 - 6.10|
On March 23, Sanofi (NASDAQ: SNY) and Regeneron's (NASDAQ: REGN) Dupixent shared positive results in its phase 3 clinical trial of patients with uncontrolled, chronic obstructive pulmonary disease (COPD). Let's take a look at the clinical data and the global COPD market to assess the sales potential of the drug.
Availability of the Q1 2023 Memorandum for modelling purposes Paris, France – March 30, 2023 - Sanofi announced today that its Q1 2023 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q1-results-2023 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various no
Sanofi (SNY) closed at $53.22 in the latest trading session, marking a +1.16% move from the prior day.